Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

NCT02146924 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

71

Enrollment

OTHER

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
OTHER: Laboratory Biomarker Analysis

Sponsor

City of Hope Medical Center

Collaborators

[object Object]